Whether Apremilast has been marketed in the country and related drug policy instructions

Apremilast (trade name: Apremilast/Otelac) is an oral phosphodiesterase 4 (PDE4) inhibitor, mainly used to treat moderate to severe plaque psoriasis. The drug has been officially launched in China and has been approved by the State Food and Drug Administration, and some specifications have been included in the National Reimbursement Catalog (Category B), providing patients with a formal channel for reimbursement through medical insurance. Patients can go to the local hospital pharmacy for consultation and purchase, and use the medicine in a standardized manner based on the guidance of a doctor. Apremilast regulates inflammatory signaling pathways and reduces the release of inflammatory mediators, thereby improving skin symptoms and itching problems, and has a significant effect on improving the quality of daily life.

In the domestic market, the price of apremilast varies slightly depending on specifications and hospitals, but overall the price is relatively affordable with the support of medical insurance. According to public information, the price of a box of 30 mg*60 tablets after medical insurance reimbursement is approximately 1,200 RMB. Patients can reduce their financial burden through medical insurance during long-term maintenance treatment. This enables apremilast to ensure efficacy while taking into account patient accessibility in domestic clinical applications, providing a practical treatment option for patients with moderate to severe psoriasis.

The overseas original version of Apremilast (Otezla) is more expensive, generally around more than 10,000 yuan, and is mainly targeted at imported drug channels and overseas patient groups. Countries such as India and Laos also have generic versions that are officially on the market. The price is much lower than the original drug, only a few hundred yuan, which significantly reduces the cost for some patients to obtain drugs through overseas channels. However, when purchasing drugs across borders, you still need to pay attention to legality and formal channels to ensure drug quality and medication safety.

Generally speaking, Apremilast has been launched in China and is included in medical insurance. Patients can purchase it through regular hospital pharmacies and use it in accordance with the guidance of doctors. The support of domestic drug policies and medical insurance coverage have improved patient accessibility. At the same time, the existence of overseas original drugs and generic drugs provides patients with different price options. Regardless of whether it is used domestically or refers to overseas channels, patients must use drugs rationally under the guidance of doctors to ensure efficacy, safety and long-term treatment sustainability.

Reference:https://reference.medscape.com/